139 related articles for article (PubMed ID: 12784318)
1. Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods.
Shin BS; Kim DH; Cho CY; Park SK; Chung SG; Cho EH; Lee SH; Joo JH; Kwon HS; Lee KC; Yoo SD
Biopharm Drug Dispos; 2003 Jul; 24(5):191-7. PubMed ID: 12784318
[TBL] [Abstract][Full Text] [Related]
2. Interspecies scaling of oleanolic acid in mice, rats, rabbits and dogs and prediction of human pharmacokinetics.
Ji HY; Shin BS; Jeong DW; Park EJ; Park ES; Yoo SD; Lee HS
Arch Pharm Res; 2009 Feb; 32(2):251-7. PubMed ID: 19280156
[TBL] [Abstract][Full Text] [Related]
3. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
Bae SK; Lee SJ; Kim YG; Kim SH; Kim JW; Kim T; Lee MG
Biopharm Drug Dispos; 2005 Apr; 26(3):99-115. PubMed ID: 15723427
[TBL] [Abstract][Full Text] [Related]
4. Interspecies pharmacokinetic scaling of DA-8159, a new erectogenic, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
Shim HJ; Kim YC; Lee JH; Kwon JW; Kim WB; Kim YG; Kim SH; Lee MG
Biopharm Drug Dispos; 2005 Oct; 26(7):269-77. PubMed ID: 15991256
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
6. Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling.
Shin BS; Bulitta JB; Balthasar JP; Kim M; Choi Y; Yoo SD
Cancer Chemother Pharmacol; 2011 Aug; 68(2):465-75. PubMed ID: 21069337
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of liquiritigenin in mice, rats, rabbits, and dogs, and animal scale-up.
Kang HE; Jung HY; Cho YK; Kim SH; Sohn SI; Baek SR; Lee MG
J Pharm Sci; 2009 Nov; 98(11):4327-42. PubMed ID: 19226634
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics of enrofloxacin in mice, rats, rabbits, sheep, and cows.
Bregante MA; Saez P; Aramayona JJ; Fraile L; Garcia MA; Solans C
Am J Vet Res; 1999 Sep; 60(9):1111-6. PubMed ID: 10490081
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic scaling of bisphenol A by species-invariant time methods.
Cho CY; Shin BS; Jung JH; Kim DH; Lee KC; Han SY; Kim HS; Lee BM; Yoo SD
Xenobiotica; 2002 Oct; 32(10):925-34. PubMed ID: 12419020
[TBL] [Abstract][Full Text] [Related]
10. Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice.
Moo KS; Radhakrishnan S; Teoh M; Narayanan P; Bukhari NI; Segarra I
Yao Xue Xue Bao; 2010 Jul; 45(7):901-8. PubMed ID: 20931790
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study on a new antiischaemic agent (BRLP-42).
Csárdi A; Pátfalusi M; Mészáros S; Vereczkey L
Acta Physiol Hung; 1994; 82(4):321-6. PubMed ID: 7785441
[TBL] [Abstract][Full Text] [Related]
13. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
[TBL] [Abstract][Full Text] [Related]
14. Disposition of abouthiouzine: a novel antihyperthyroid drug.
Alkharfy KM; Khan RM; Al-Hadiya BM; Abou-Auda HS; Abou-Shaaban RR
Biopharm Drug Dispos; 2007 Apr; 28(3):105-11. PubMed ID: 17230598
[TBL] [Abstract][Full Text] [Related]
15. Interspecies scaling of a camptothecin analogue: human predictions for intravenous topotecan using animal data.
Ahlawat P; Srinivas NR
Xenobiotica; 2008 Nov; 38(11):1377-85. PubMed ID: 18946781
[TBL] [Abstract][Full Text] [Related]
16. Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2.
Bazin-Redureau M; Pepin S; Hong G; Debray M; Scherrmann JM
Toxicol Appl Pharmacol; 1998 Jun; 150(2):295-300. PubMed ID: 9653060
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Hosagrahara VP; Chandrasena G; Chang SY; Koplowitz B; Hariharan N; Cheng PT; Humphreys WG
Xenobiotica; 2006 Dec; 36(12):1227-38. PubMed ID: 17162469
[TBL] [Abstract][Full Text] [Related]
19. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
[TBL] [Abstract][Full Text] [Related]
20. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin.
Jolling K; Perez Ruixo JJ; Hemeryck A; Vermeulen A; Greway T
Eur J Pharm Sci; 2005 Apr; 24(5):465-75. PubMed ID: 15784336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
